There are 2789 resources available
663P - First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
664P - Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors
Presenter: Andre Kydd
Session: ePoster Display
648TiP - PSMAfore: A phase III study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Presenter: Michael Morris
Session: ePoster Display
727P - Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
Presenter: Alexandra Leary
Session: ePoster Display
660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Presenter: Toni Choueiri
Session: ePoster Display
729P - Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)
Presenter: Judith Kroep
Session: ePoster Display
730P - Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
Presenter: Huaying Wang
Session: ePoster Display
731P - Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study
Presenter: Robert Morgan
Session: ePoster Display
732P - Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Presenter: Jueming Chen
Session: ePoster Display